Please see Request for Applications for more information regarding eligibility and procedures to apply.
Application deadline is November 4, 2022
Apply Here  


Dec 6th, 2022

BBRB 170


 Welcome - Dr. Carlos Orihuela and Dr. Kathy Hancock  



Student Presentation #1


Nitrosative stress: Mediator of commensal-pathogen interactions in the airway

Josh Baty 

Scoffield Lab


Student Presentation #2


Molecular Determinants of Retroviral Gag Assembly at the Plasma Membrane

 Dominik Herrmann

Saad Lab


Student Presentation #3

 sara stoner

 Pseudomonas aeruginosa promotes commensal streptococcus biofilm development and airway colonization 

Sara Stoner

Scoffield Lab 




David E. Wells Guest Lecturer

 Ollmann Saphire

Antibody defense against emerging infectious disease

Dr. Erica Ollmann Saphire, Ph.D.

Professor, President & Chief Executive Officer 

La Jolla Institute for Immunology


Announcement of the of David E. Wells Research Award


Closing Remarks followed by reception in lobby

Dr. Erica Ollmann Saphire, Ph.D. 

Her research explains, at the molecular level, how and why viruses are pathogenic and provides the roadmap for medical defense. Her team has solved the structures of the Ebola, Sudan, Marburg, Bundibugyo and Lassa virus glycoproteins, explained how they remodel these structures as they drive themselves into cells, how their proteins suppress immune function and where human antibodies can defeat these viruses.

Prof. Saphire is currently leading a Bill & Melinda Gates Foundation-supported consortium to evaluate antibody therapeutics against SARS-CoV-2 to prevent and treat COVID-19. This consortium, CoVIC ( analyzes the world’s leading therapeutic candidates side-by- side, and uses LJI’s powerful pair of Titan Krios microscopes for high-resolution analysis of the antibody interactions.

She was also the galvanizing force behind the Viral Hemorrhagic Fever Immunotherapeutic Consortium and is directing this NIAID-supported organization. This consortium, Center of Excellence in Translational Research, unites 44 previously competing academic, industrial and government labs across five continents to understand and provide antibody therapeutics against Ebola, Marburg, Lassa and other viruses. A recent discovery from Instructor Kathryn Hastie revealed why neutralizing antibodies had been so difficult to elicit against Lassa virus, and provided not only the templates for the needed vaccine, but the molecule itself: a Lassa surface glycoprotein engineered to remain in the right conformation to inspire the needed antibody response. This molecule is the basis for international vaccine efforts against Lassa. Other work in their lab reveals how these and other viruses replicate and assemble using a variety of biophysical, biochemical, and immunological methods.

Dr. Saphire’s work has been recognized at the White House with the Presidential Early Career Award in Science and Engineering, with young investigator awards from the International Congress of Antiviral Research, the American Society for Microbiology, and the MRC Centre for Virus Research in the United Kingdom. She has been awarded a Fulbright Global Scholar fellowship from the United States Department of State and a Mercator Fellowship from Deutsche Forschungsgemeinschaft, to develop international collaborations using cryoelectron microscopy to further global health.